SAN DIEGO, Feb. 27, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2017, and provided an update on its corporate activities and product pipeline. "I am pleased to share Cidara's progress during the fourth quarter of 2017 and subsequently. Our accomplishments included the completion of enrollment in our STRIVE Phase 2 clinical trial of rezafungin…

Data Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections in Immunocompromised Patients SAN DIEGO, Jan. 29, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its lead antifungal candidate rezafungin acetate, formerly known as CD101 IV, will be presented at two upcoming medical conferences. Rezafungin abstracts have been accepted for presentation at both the 8th Advances…

Authors Highlight How New Options Can be Used to Augment Antifungal Treatment and Prophylaxis Strategies SAN DIEGO, Jan. 04, 2018 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that a new compendium of papers published as a Journal of Antimicrobial Chemotherapy supplement reviews evidence and provides insights into the future of echinocandin therapy, including strategies for the treatment and prevention of life-threatening invasive fungal infections. "Fungal infections are…

Topline Data Expected in First Quarter 2018 SAN DIEGO, Nov. 28, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the STRIVE trial, a Phase 2 randomized clinical trial evaluating the safety, tolerability and efficacy of once-weekly dosing of its lead antifungal candidate rezafungin acetate, formerly known as CD101 IV, compared to once-daily dosing of caspofungin in patients with candidemia and invasive…

Employee feedback places company among top 10 in San Diego Metro Area SAN DIEGO, Nov. 13, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a 2017 Top Workplace by The San Diego Union-Tribune. Top Workplaces lists are based solely on the results of an annual employee survey administered by Energage, LLC, a leading, independent research firm. Surveys measure several aspects of workplace…

Conference call and webcast today at 1:05 p.m. PST/4:05 p.m. EST SAN DIEGO, Nov. 08, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2017 and provided an update on its corporate activities and product pipeline. "We are pleased to report Cidara's continued progress during the third quarter of 2017 and subsequently, including receiving clarity on the regulatory path…

SAN DIEGO, Nov. 01, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will report third quarter 2017 financial results after the close of U.S. financial markets on November 8, 2017. Cidara's management will host a webcast and conference call at 4:05 p.m. EST/1:05 p.m. PST that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing…

SAN DIEGO, Oct. 19, 2017 -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the pricing of a private placement of 3,360,000 shares of its common stock at a price of $6.00 per share. The syndicate of investors in the private placement was comprised of new and existing investors, including Great Point Partners, LLC, BB Biotech AG, Prosight Capital, Broadfin Capital, LLC and certain other institutional investors. The gross…

Data Highlight Advantages of CD101 in Difficult-to-Treat Infections SAN DIEGO, Sept. 25, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its novel echinocandin antifungal CD101 will be presented at two upcoming infectious disease meetings. CD101 abstracts have been accepted for presentation at both IDWeek 2017 in San Diego from October 4-8 and at the 8th Trends in Medical Mycology (TIMM) meeting…

SAN DIEGO, Sept. 18, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at two upcoming investor conferences. Cantor Fitzgerald 2017 Global Healthcare Conference, New York, September 25, 2017 at 10:20 a.m. EDT (7:20 a.m. PDT)Ladenburg Thalmann 2017 Healthcare Conference, New York, September 26, 2017 at 8:30 a.m. EDT (5:30 a.m. PDT) A…